Characteristics‡ | Consented | Declined | Not approached |  |
---|---|---|---|---|
 | (n =1861) | (n =216) | (n =502) | p value |
Site | Â | Â | Â | Â |
  Windsor | 128 (7%) | <6 (<3%) | 94 (19%) | <.0001 |
  UHN | 525 (28%) | 162 (75%) | 226 (45%) |  |
  Ottawa | 293 (16%) | 35 (16%) | 123 (25%) |  |
  MLMC | 915 (49%) | <16 (<7%) | 59 (12%) |  |
Age | 46 (40–52) | 45 (37–51) | 44 (39–50) | 0.008 |
Male | 1632 (88%) | 154 (71%) | 374 (75%) | <.0001 |
Risk Factor | Â | Â | Â | Â |
  MSM | 1429 (77%) | 90 (42%) | 229 (47%) | <.0001 |
  IDU | 180 (10%) | 13 (6%) | 49 (10%) | 0.19 |
  Heterosexual | 325 (18%) | 93 (43%) | 177 (36%) | <.0001 |
  Blood product | 100 (5%) | 10 (5%) | 30 (7%) | 0.46 |
Race | Â | Â | Â | Â |
  Caucasian | 1329 (72%) | 76 (41%) | 240 (57%) | <.0001 |
  Black/African | 259 (14%) | 75 (40%) | 129 (31%) |  |
  Other | 259 (10%) | 35 (19%) | 49 (11%) |  |
Born in Canada | 1264 (69%) | 78 (39%) | 224 (52%) | <.0001 |
Years since HIV+ test | 12 (5–18) | 7 (5–14) | 8 (4–13) | <.0001 |
On cART | 1487 (80%) | 156 (73%) | 362 (73%) | 0.001 |
CD4 count (cells/mm3) | 480 (340–650) | 450 (296–615) | 420 (281–587) | <.0001 |
  <200 | 155 (8%) | 31 (14%) | 70 (15%) | <.0001 |
  200-500 | 851 (46%) | 102 (47%) | 227 (47%) |  |
  >500 | 853 (46%) | 82 (38%) | 185 (38%) |  |
VL <50 copies/mL | 1379 (74%) | 160 (75%) | 297 (62%) | <.0001 |